119th Congress · introduced in the House · Apr 1, 2025
Old Drugs, New Cures Act
Official title from Congress.gov
Latest action (Apr 1, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Apr 1, 2025)
Old Drugs, New Cures Act
This bill exempts manufacturers of certain long-standing drugs from paying specialized rebates under the Medicaid Drug Rebate Program and the Medicare Prescription Drug Inflation Rebate Program. (Under these programs, drug manufacturers pay rebates to state Medicaid programs for certain drugs covered under Medicaid and to the Centers for Medicare & Medicaid Services for certain drugs covered under Medicare.)
Specifically, manufacturers may request that a drug that would otherwise be considered a line extension under the Medicaid and Medicare rebate programs to instead be designated as a priority research drug. (A line extension refers to an oral dose of a new formulation of an existing drug, such as an extended release formulation, that would subject the drug to specialized rebates under the Medicaid and Medicare drug rebate programs.)
Under the bill, a drug qualifies as a priority research drug if (1) at least 10 years have elapsed since the drug was first approved, (2) the manufacturer is investigating a new use of the drug that would address a significant unmet need, and (3) the new use addresses a disease or condition that has a high prevalence among beneficiaries of Medicaid, Medicare, or other federal health care programs.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
7 citations.
BAUSCH HEALTH · lobbying firm or registrant: CAPITOL HILL CONSULTING GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
Issues surrounding Medicare and Medicaid coverage of prescription drugs, including H.R. 2542, the Old Drugs, New Cures Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAUSCH HEALTH · lobbying firm or registrant: CAPITOL HILL CONSULTING GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
Issues surrounding Medicare and Medicaid coverage of prescription drugs, including H.R. 2542, the Old Drugs, New Cures Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAUSCH HEALTH · lobbying firm or registrant: CAPITOL HILL CONSULTING GROUP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 21, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
Issues surrounding Medicare and Medicaid coverage of prescription drugs, including H.R. 2542, the Old Drugs, New Cures Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAUSCH HEALTH · lobbying firm or registrant: CAPITOL HILL CONSULTING GROUP
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
Issues surrounding Medicare and Medicaid coverage of prescription drugs, including H.R. 2542, the Old Drugs, New Cures Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAUSCH HEALTH · lobbying firm or registrant: CAPITOL HILL CONSULTING GROUP
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$30,000
Paid to lobbying firm
Issues surrounding Medicare and Medicaid coverage of prescription drugs, including H.R. 2542, the Old Drugs, New Cures Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAUSCH HEALTH · lobbying firm or registrant: CAPITOL HILL CONSULTING GROUP
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$30,000
Paid to lobbying firm
Issues surrounding Medicare and Medicaid coverage of prescription drugs, including H.R. 2542, the Old Drugs, New Cures Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BAUSCH HEALTH · lobbying firm or registrant: CAPITOL HILL CONSULTING GROUP
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 21, 2025 · issue area: Health Issues
$30,000
Paid to lobbying firm
Medicare and Medicaid payment policies. H.R.2542
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing